Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis.

ABSTRACT: Aspirin therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether aspirin therapy lowers the risk of HCC in patients with alcoholic cirrhosis.A retrospective analysis of data from 949 consecutive patients with alcoholic cirrhosis who abstained from alcoholic drinking was performed. The primary and secondary outcomes were development of HCC and gastrointestinal bleeding events, respectively. Risk was compared between patients with aspirin treatment and patients who were not treated (non-aspirin group) using a time-varying Cox proportional hazards model for total population and propensity score-matching analysis.The aspirin group included 224 patients and the non-aspirin group had 725 patients. During the study period o

SUBMITTER: Shin S 

PROVIDER: S-EPMC7478404 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature